Morphology of bi- cuspid aortic valve in children and adolescents. J Am Coll Cardiol. 2004;44:1648 51. S4.2.4-2. Biner S, Rafique AM, Ray I, et al. Aortopathy is prevalent in relatives of bicuspid aortic valve patients. J Am Coll Cardiol. 2009;53:2288 95. S4.2.4-3. Tutar E, Ekici F, Atalay S, et al. The prevalence of bicuspid aortic valve in newborns by echocardiographic screening. Am Heart J. 2005;150:513 5. S4.2.4-4. Huntington K, Hunter AG, Chan KL. A prospective study to assess the frequency of familial clustering of congenital bicuspid aortic valve. J Am Coll Cardiol. 1997;30:1809 12. S4.2.4-5. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:e521 643. S4.2.4-6. Arora R, Jolly N, Bhat A, et al. Follow-up of balloon aortic valvu- loplasty in young adults a combined hemodynamic and Doppler echocardiographic study. Indian Heart J. 1989;41:314 7. CLINICAL STATEMENTS AND GUIDELINES S4.2.4-7. Aboulhosn J, Child JS. Left ventricular outflow obstruction: subaor- tic stenosis, bicuspid aortic valve, supravalvar aortic stenosis, and coarctation of the aorta. Circulation. 2006;114:2412 22. S4.2.4-8. Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol. 2010;55:2789 800. S4.2.4-9. Reifenstein GH, Levine SA, Gross RE. Coarctation of the aorta; a review of 104 autopsied cases of the adult type, 2 years of age or older. Am Heart J. 1947;33:146 68. S4.2.4-10. Roos-Hesselink JW, Sch lzel BE, Heijdra RJ, et al. Aortic valve and aortic arch pathology after coarctation repair. Heart. 2003;89:1074 7. S4.2.4-11. Stewart AB, Ahmed R, Travill CM, et al. Coarctation of the aorta life and health 20 44 years after surgical repair. Br Heart J. 1993;69:65 70. S4.2.4-12. Presbitero P, Demarie D, Villani M, et al. Long term results 15 30 years) of surgical repair of aortic coarctation. Br Heart J. 1987;57:462 7. S4.2.4-13. Abbott ME. Coarctation of the aorta of the adult type, II: a statis- tical and historical retrospect of 200 recorded cases with autopsy, of stenosis or obliteration of the descending arch in subjects above the age of 2 years. Am Heart J. 1928;3:574 618. S4.2.4-14. Hashimoto H, Tamura T, Ikari Y, et al. Comparison of aortic valve replacement and percutaneous aortic balloon valvuloplasty for eld- erly patients with aortic stenosis. Jpn Circ J. 1996;60:142 8. S4.2.4-15. Klein A, Lee K, Gera A, et al. Long-term mortality, cause of death, and temporal trends in complications after percutaneous aortic balloon valvuloplasty for calcific aortic stenosis. J Interv Cardiol. 2006;19:269 75. 4.2.4.1. Turner Syndrome S4.2.4.1-1. Sybert VP. Cardiovascular malformations and complications in Turner syndrome. Pediatrics. 1998;101:E11. S4.2.4.1-2. Carlson M, Airhart N, Lopez L, et al. Moderate aortic enlargement and bicuspid aortic valve are associated with aortic dissection in Turner syndrome: report of the International Turner Syndrome Aortic Dissection Registry. Circulation. 2012;126:2220 6. S4.2.4.1-3. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart di- sease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:e521 643. S4.2.4.1-4. Karnis MF, Zimon AE, Lalwani SI, et al. Risk of death in pregnancy achieved through oocyte donation in patients with Turner syn- drome: a national survey. Fertil Steril. 2003;80:498 501. S4.2.4.1-5. Svensson LG, Khitin L. Aortic cross-sectional area/height ratio tim- ing of aortic surgery in asymptomatic patients with Marfan syn- drome. J Thorac Cardiovasc Surg. 2002;123:360 1. S4.2.4.1-6. Svensson LG, Kim K-H, Lytle BW, et al. Relationship of aortic cross-sectional area to height ratio and the risk of aortic dissection in patients with bicuspid aortic valves. J Thorac Cardiovasc Surg. 2003;126:892 3. S4.2.4.1-7. Quezada E, Lapidus J, Shaughnessy R, et al. Aortic dimensions in Turner syndrome. Am J Med Genet A. 2015;167A:2527 32. S4.2.4.2-1. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart di- sease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:e521 643. S4.2.4.2-2. Svensson LG, Adams DH, Bonow RO, et al. Aortic valve and as- cending aorta guidelines for management and quality measures. Ann Thorac Surg. 2013;95:S1 66. S4.2.4.2-3. Hiratzka LF, Creager MA, Isselbacher EM, et al. Surgery for aortic dilatation in patients with bicuspid aortic valves: a statement of clarification from the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2015;133:680 6. S4.2.4.2-4. Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA. 2011;306:1104 12. S4.2.4.2-5. Kaya A, Heijmen RH, Vreuls W, et al. Chronic type A dissection in a pulmonary autograft. J Heart Valve Dis. 2007;16:162 4. S4.2.4.2-6. Hutter PA, Thomeer BJ, Jansen P, et al. Fate of the aortic root after arterial switch operation. Eur J Cardiothorac Surg. 2001;20:82 8. S4.2.4.2-7. Marino BS, Wernovsky G, McElhinney DB, et al. Neo-aortic valvar function after the arterial switch. Cardiol Young. 2006;16:481 9. S4.2.4.2-8. Schwartz ML, Gauvreau K, del Nido P, et al. Long-term predictors of aortic root dilation and aortic regurgitation after arterial switch operation. Circulation. 2004;110:II128 32. S4.2.4.2-9. Mongeon F-P, Gurvitz MZ, Broberg CS, et al. Aortic root dilatation in adults with surgically repaired tetralogy of Fallot: a multicenter cross-sectional study. Circulation. 2013;127:172 9. S4.2.4.2-10. Egan M, Phillips A, Cook SC. Aortic dissection in the adult Fontan with aortic root enlargement. Pediatr Cardiol. 2009;30: 562 3. S4.2.4.2-11. Wijesekera VA, Kiess MC, Grewal J, et al. Aortic dissection in a pa- tient with a dilated aortic root following tetralogy of Fallot repair. Int J Cardiol. 2014;174:833 4. S4.2.4.2-12. Konstantinov IE, Fricke TA, d'Udekem Y, et al. Aortic dissection and rupture in adolescents after tetralogy of Fallot repair. J Thorac Cardiovasc Surg. 2010;140:e71 3. S4.2.4.2-13. Kim W-H, Seo J-W, Kim S-J, et al. Aortic dissection late after repair of tetralogy of Fallot. Int J Cardiol. 2005;101:515 6. S4.2.4.2-14. Rathi VK, Doyle M, Williams RB, et al. Massive aortic aneu- rysm and dissection in repaired tetralogy of Fallot; diagnosis by cardiovascular magnetic resonance imaging. Int J Cardiol. 2005;101:169 70. S4.2.4.2-15. Stulak JM, Dearani JA, Burkhart HM, et al. Does the dilated as- cending aorta in an adult with congenital heart disease require intervention? J Thorac Cardiovasc Surg. 2010;140:S52 7. 4.2.5. Supravalvular Aortic Stenosis S4.2.5-1. Tani LY, Minich LL, Pagotto LT, et al. Usefulness of doppler echocar- diography to determine the timing of surgery for supravalvar aortic stenosis. Am J Cardiol. 2000;86:114 6. S4.2.5-2. Thiene G, Ho SY. Aortic root pathology and sudden death in youth: review of anatomical varieties. Appl Pathol. 1986;4:237 45. S4.2.5-3. Stamm C, Li J, Ho SY, et al. The aortic root in supravalvular aortic stenosis: the potential surgical relevance of morphologic findings. J Thorac Cardiovasc Surg. 1997;114:16 24. S4.2.5-4. Martin MM, Lemmer JH Jr, Shaffer E, et al. Obstruction to left coronary artery blood flow secondary to obliteration of the cor- onary ostium in supravalvular aortic stenosis. Ann Thorac Surg. 1988;45:16 20. S4.2.5-5. Bruno E, Rossi N, Th er O, et al. Cardiovascular findings, and clin- ical course, in patients with Williams syndrome. Cardiol Young. 2003;13:532 6. S4.2.5-6. Wren C, Oslizlok P, Bull C. Natural history of supravalvular aortic stenosis and pulmonary artery stenosis. J Am Coll Cardiol. 1990;15:1625 30. S4.2.5-7. Eronen M, Peippo M, Hiippala A, et al. Cardiovascular manifes- tations in 75 patients with Williams syndrome. J Med Genet. 2002;39:554 8. S4.2.5-8. Greutmann M, Tobler D, Sharma NC, et al. Cardiac out- comes in adults with supravalvar aortic stenosis. Eur Heart J. 2012;33:2442 50. S4.2.5-9. Doty DB, Eastham CL, Hiratzka LF, et al. Determination of coronary reserve in patients with supravalvular aortic stenosis. Circulation. 1982;66:I186 92. S4.2.5-10. Bird LM, Billman GF, Lacro RV, et al. Sudden death in Williams syn- drome: report of ten cases. J Pediatr. 1996;129:926 31. S4.2.5-11. Bragg K, Fedel GM, DiProsperis A. Cardiac arrest under anesthesia in a pediatric patient with Williams syndrome: a case report. AANA J. 2005;73:287 93. S4.2.5-12. Gupta P, Tobias JD, Goyal S, et al. Sudden cardiac death under an- esthesia in pediatric patient with Williams syndrome: a case report and review of literature. Ann Card Anaesth. 2010;13:44 8. S4.2.5-13. Horowitz PE, Akhtar S, Wulff JA, et al. Coronary artery disease and anesthesia-related death in children with Williams syndrome. J Cardiothorac Vasc Anesth. 2002;16:739 41. S4.2.5-14. Monfared A, Messner A. Death following tonsillectomy in a child with Williams syndrome. Int J Pediatr Otorhinolaryngol. 2006;70:1133 5. S4.2.5-15. Aboulhosn J, Child JS. Echocardiographic evaluation of congenital left ventricular outflow obstruction. Echocardiography. 2015;32 suppl 2:S140 7. CLINICAL STATEMENTS AND GUIDELINES 4.2.6. Coarctation of the Aorta S4.2.6-1. Qureshi AM, McElhinney DB, Lock JE, et al. Acute and intermediate outcomes, and evaluation of injury to the aortic wall, as based on 15 years experience of implanting stents to treat aortic coarctation. Cardiol Young. 2007;17:307 18. S4.2.6-2. Hager A, Kanz S, Kaemmerer H, et al. Coarctation Long-term Assessment (COALA): significance of arterial hypertension in a cohort of 404 patients up to 27 years after surgical repair of isolated coarctation of the aorta, even in the absence of re- stenosis and prosthetic material. J Thorac Cardiovasc Surg. 2007;134:738 45. S4.2.6-3. Forbes TJ, Garekar S, Amin Z, et al. Procedural results and acute complications in stenting native and recurrent coarctation of the aorta in patients over 4 years of age: a multi-institutional study. Catheter Cardiovasc Interv. 2007;70:276 85. S4.2.6-4. Morgan GJ, Lee KJ, Chaturvedi R, et al. Systemic blood pressure after stent management for arch coarctation implications for clin- ical care. JACC Cardiovasc Interv. 2013;6:192 201. S4.2.6-5. Cook SC, Hickey J, Maul TM, et al. Assessment of the cerebral circulation in adults with coarctation of the aorta. Congenit Heart Dis. 2013;8:289 95. S4.2.6-6. Connolly HM, Huston J 3rd, Brown RD Jr, et al. Intracranial aneu- rysms in patients with coarctation of the aorta: a prospective mag- netic resonance angiographic study of 100 patients. Mayo Clin Proc. 2003;78:1491 9. S4.2.6-7. Correia AS, Gon alves A, Paiva M, et al. Long-term follow-up after aortic coarctation repair: the unsolved issue of exercise-induced hy- pertension. Rev Port Cardiol. 2013;32:879 83. S4.2.6-8. Holzer R, Qureshi S, Ghasemi A, et al. Stenting of aortic coarc- tation: acute, intermediate, and long-term results of a pro- spective multi-institutional registry Congenital Cardiovascular Interventional Study Consortium (CCISC). Catheter Cardiovasc Interv. 2010;76:553 63. S4.2.6-9. Chessa M, Carrozza M, Butera G, et al. Results and mid-long-term follow-up of stent implantation for native and recurrent coarcta- tion of the aorta. Eur Heart J. 2005;26:2728 32. S4.2.6-10. Toro-Salazar OH, Steinberger J, Thomas W, et al. Long-term fol- low-up of patients after coarctation of the aorta repair. Am J Cardiol. 2002;89:541 7. S4.2.6-11. Carr JA. The results of catheter-based therapy compared with surgical repair of adult aortic coarctation. J Am Coll Cardiol. 2006;47:1101 7. S4.2.6-12. Brown JW, Ruzmetov M, Hoyer MH, et al. Recurrent coarctation: is surgical repair of recurrent coarctation of the aorta safe and effec- tive? Ann Thorac Surg. 2009;88:1923 30. S4.2.6-13. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206 52. S4.2.6-14. Su rez de Lezo J, Pan M, Romero M, et al. Percutaneous inter- ventions on severe coarctation of the aorta: a 21-year experience. Pediatr Cardiol. 2005;26:176 89. S4.2.6-15. Aboulhosn J, Child JS. Left ventricular outflow obstruction: subaor- tic stenosis, bicuspid aortic valve, supravalvar aortic stenosis, and coarctation of the aorta. Circulation. 2006;114:2412 22. S4.2.6-16. Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol. 2010;55:2789 800. S4.2.6-17. Reifenstein GH, Levine SA, Gross RE. Coarctation of the aorta; a review of 104 autopsied cases of the adult type, 2 years of age or older. Am Heart J. 1947;33:146 68. S4.2.6-18. Roos-Hesselink JW, Sch lzel BE, Heijdra RJ, et al. Aortic valve and aortic arch pathology after coarctation repair. Heart. 2003;89:1074 7. S4.2.6-19. Stewart AB, Ahmed R, Travill CM, et al. Coarctation of the aorta life and health 20 44 years after surgical repair. Br Heart J. 1993;69:65 70. S4.2.6-20. Presbitero P, Demarie D, Villani M, et al. Long term results 15 30 years) of surgical repair of aortic coarctation. Br Heart J. 1987;57:462 7. S4.2.6-21. Abbott ME. Coarctation of the aorta of the adult type, II: a statis- tical and historical retrospect of 200 recorded cases with autopsy, of stenosis or obliteration of the descending arch in subjects above the age of 2 years. Am Heart J. 1928;3:574 618. S4.2.6-22. Wiebers DO, Whisnant JP, Huston J 3rd, et al. Unruptured intra- cranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362:103 10. S4.2.6-23. Donti A, Spinardi L, Brighenti M, et al. Frequency of intracranial aneurysms determined by magnetic resonance angiography in children (mean age 16) having operative or endovascular treat- ment of coarctation of the aorta (mean age 3). Am J Cardiol. 2015;116:630 3. S4.2.6-24. Krieger EV, Clair M, Opotowsky AR, et al. Correlation of exercise response in repaired coarctation of the aorta to left ventricular mass and geometry. Am J Cardiol. 2013;111:406 11. S4.2.6-25. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/ AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13 115. 4.3. Right-Sided Lesions 4.3.1. Valvular Pulmonary Stenosis S4.3.1-1. Voet A, Rega F, de Bruaene AV, et al. Long-term outcome after treatment of isolated pulmonary valve stenosis. Int J Cardiol. 2012;156:11 5. S4.3.1-2. Kaul UA, Singh B, Tyagi S, et al. Long-term results after balloon pulmonary valvuloplasty in adults. Am Heart J. 1993;126:1152 5. S4.3.1-3. Chen CR, Cheng TO, Huang T, et al. Percutaneous balloon valvu- loplasty for pulmonic stenosis in adolescents and adults. N Engl J Med. 1996;335:21 5. S4.3.1-4. Taggart NW, Cetta F, Cabalka AK, et al. Outcomes for balloon pul- monary valvuloplasty in adults: comparison with a concurrent pe- diatric cohort. Catheter Cardiovasc Interv. 2013;82:811 5. S4.3.1-5. Kopecky SL, Gersh BJ, McGoon MD, et al. Long-term out- come of patients undergoing surgical repair of isolated pul- monary valve stenosis. Follow-up at 20 30 years. Circulation. 1988;78:1150 6. S4.3.1-6. Hayes CJ, Gersony WM, Driscoll DJ, et al. Second natural history study of congenital heart defects. Results of treatment of patients with pulmonary valvar stenosis. Circulation. 1993;87:I28 37. S4.3.1-7. Roos-Hesselink JW, Meijboom FJ, Spitaels SEC, et al. Long-term outcome after surgery for pulmonary stenosis (a longitudinal study of 22 33 years). Eur Heart J. 2006;27:482 8. S4.3.1-8. Earing MG, Connolly HM, Dearani JA, et al. Long-term follow-up of patients after surgical treatment for isolated pulmonary valve stenosis. Mayo Clin Proc. 2005;80:871 6. S4.3.1-9. Moss AJ, Adams FH, Emmanouilides GC. Moss and Adams Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adult. 5th ed. Baltimore, MD: Williams & Wilkins, 1995. S4.3.1-10. Stephensen SS, Sigfusson G, Eiriksson H, et al. Congenital cardiac malformations in Iceland from 1990 through 1999 Cardiol Young. 2004;14:396 401. S4.3.1-11. Sam nek M, Slav k Z, Zborilov B, et al. Prevalence, treatment, and outcome of heart disease in live-born children: a prospective anal- ysis of 91,823 live-born children. Pediatr Cardiol. 1989;10:205 11. S4.3.1-12. Cuypers JAAE, Witsenburg M, van der Linde D, et al. Pulmonary stenosis: update on diagnosis and therapeutic options. Heart. 2013;99:339 47. S4.3.1-13. Schneider AW, Blom NA, Bruggemans EF, et al. More than 25 years of experience in managing pulmonary atresia with intact ventric- ular septum. Ann Thorac Surg. 2014;98:1680 6. S4.3.1-14. John AS, Warnes CA. Clinical outcomes of adult survivors of pulmonary atresia with intact ventricular septum. Int J Cardiol. 2012;161:13 7. S4.3.1-15. Liang X-C, Lam WWM, Cheung EWY, et al. Restrictive right ventric- ular physiology and right ventricular fibrosis as assessed by cardiac magnetic resonance and exercise capacity after biventricular repair of pulmonary atresia and intact ventricular septum. Clin Cardiol. 2010;33:104 10. S4.3.1-16. Mishima A, Asano M, Sasaki S, et al. Long-term outcome for right heart function after biventricular repair of pulmonary atresia and intact ventricular septum. Jpn J Thorac Cardiovasc Surg. 2000;48:145 52. CLINICAL STATEMENTS AND GUIDELINES 4.3.1.1. Isolated PR After Repair of PS S4.3.1.1-1. Zdradzinski MJ, Qureshi AM, Stewart R, et al. Comparison of long-term postoperative sequelae in patients with tetralogy of Fallot versus isolated pulmonic stenosis. Am J Cardiol. 2014;114: 300 4. 4.3.2. Branch and Peripheral Pulmonary Stenosis S4.3.2-1. Hallbergson A, Lock JE, Marshall AC. Frequency and risk of in- stent stenosis following pulmonary artery stenting. Am J Cardiol. 2014;113:541 5. S4.3.2-2. Gonzalez I, Kenny D, Slyder S, et al. Medium and long-term outcomes after bilateral pulmonary artery stenting in chil- dren and adults with congenital heart disease. Pediatr Cardiol. 2013;34:179 84. S4.3.2-3. Kenny D, Amin Z, Slyder S, et al. Medium-term outcomes for pe- ripheral pulmonary artery stenting in adults with congenital heart disease. J Interv Cardiol. 2011;24:373 7. 4.3.3. Double-Chambered Right Ventricle S4.3.3-1. Hachiro Y, Takagi N, Koyanagi T, et al. Repair of double-chambered right ventricle: surgical results and long-term follow-up. Ann Thorac Surg. 2001;72:1520 2. S4.3.3-2. Kveselis D, Rosenthal A, Ferguson P, et al. Long-term prognosis after repair of double-chamber right ventricle with ventricular septal defect. Am J Cardiol. 1984;54:1292 5. S4.3.3-3. Said SM, Burkhart HM, Dearani JA, et al. Outcomes of surgical repair of double-chambered right ventricle. Ann Thorac Surg. 2012;93:197 200. S4.3.3-4. Kahr PC, Alonso-Gonzalez R, Kempny A, et al. Long-term nat- ural history and postoperative outcome of double-chambered right ventricle experience from two tertiary adult congenital heart centres and review of the literature. Int J Cardiol. 2014;174: 662 8. S4.3.3-5. Pongiglione G, Freedom RM, Cook D, et al. Mechanism of acquired right ventricular outflow tract obstruction in patients with ven- tricular septal defect: an angiocardiographic study. Am J Cardiol. 1982;50:776 80. S4.3.3-6. Oliver JM, Garrido A, Gonzalez A, et al. Rapid progression of mid- ventricular obstruction in adults with double-chambered right ven- tricle. J Thorac Cardiovasc Surg. 2003;126:711 7. 4.3.4. Ebstein Anomaly S4.3.4-1. Bharucha T, Anderson RH, Lim ZS, et al. Multiplanar review of three-dimensional echocardiography gives new insights into the morphology of Ebstein s malformation. Cardiol Young. 2010;20:49 53. S4.3.4-2. Attenhofer Jost CH, Edmister WD, Julsrud PR, et al. Prospective comparison of echocardiography versus cardiac magnetic reso- nance imaging in patients with Ebstein s anomaly. Int J Cardiovasc Imaging. 2012;28:1147 59. S4.3.4-3. Wei W, Zhan X, Xue Y, et al. Features of accessory pathways in adult Ebstein s anomaly. Europace. 2014;16:1619 25. S4.3.4-4. Iturralde P, Nava S, S lica G, et al. Electrocardiographic characteris- tics of patients with Ebstein s anomaly before and after ablation of an accessory atrioventricular pathway. J Cardiovasc Electrophysiol. 2006;17:1332 6. S4.3.4-5. Shivapour JKL, Sherwin ED, Alexander ME, et al. Utility of preoper- ative electrophysiologic studies in patients with Ebstein s anomaly undergoing the cone procedure. Heart Rhythm. 2014;11:182 6. S4.3.4-6. Raju V, Dearani JA, Burkhart HM, et al. Right ventricular unloading for heart failure related to Ebstein malformation. Ann Thorac Surg. 2014;98:167 73. S4.3.4-7. Brown ML, Dearani JA, Danielson GK, et al. The outcomes of oper- ations for 539 patients with Ebstein anomaly. J Thorac Cardiovasc Surg. 2008;135:1120 36; e1-7. S4.3.4-8. Dearani JA, Said SM, Burkhart HM, et al. Strategies for tricuspid re-repair in Ebstein malformation using the cone technique. Ann Thorac Surg. 2013;96:202 8. S4.3.4-9. Dearani JA, Said SM, O'Leary PW, et al. Anatomic repair of Ebstein s malformation: lessons learned with cone reconstruction. Ann Thorac Surg. 2013;95:220 6. S4.3.4-10. Badiu CC, Schreiber C, H rer J, et al. Early timing of surgical inter- vention in patients with Ebstein s anomaly predicts superior long- term outcome. Eur J Cardiothorac Surg. 2010;37:186 92. S4.3.4-11. Khositseth A, Danielson GK, Dearani JA, et al. Supraventricular tachyarrhythmias in Ebstein anomaly: management and outcome. J Thorac Cardiovasc Surg. 2004;128:826 33. S4.3.4-12. Zachariah JP, Walsh EP, Triedman JK, et al. Multiple accessory path- ways in the young: the impact of structural heart disease. Am Heart J. 2013;165:87 92. S4.3.4-13. Chauvaud S. Ebstein s malformation. Surgical treatment and results. Thorac Cardiovasc Surg. 2000;48:220 3. S4.3.4-14. Chen JM, Mosca RS, Altmann K, et al. Early and medium-term results for repair of Ebstein anomaly. J Thorac Cardiovasc Surg. 2004;127:990 8. S4.3.4-15. Malhotra SP, Petrossian E, Reddy VM, et al. Selective right ventric- ular unloading and novel technical concepts in Ebstein s anomaly. Ann Thorac Surg. 2009;88:1975 81. S4.3.4-16. Lupo PJ, Langlois PH, Mitchell LE. Epidemiology of Ebstein anomaly: Prevalence and patterns in Texas, 1999 2005 Am J Med Genet Part A. 2011;155A:1007 14. S4.3.4-17. Correa-Villase or A, Ferencz C, Neill CA, et al. Ebstein s malfor- mation of the tricuspid valve: genetic and environmental fac- tors. The Baltimore-Washington Infant Study Group. Teratology. 1994;50:137 47. S4.3.4-18. Pradat P, Francannet C, Harris JA, et al. The epidemiology of cardiovascular defects, part I: a study based on data from three large registries of congenital malformations. Pediatr Cardiol. 2003;24:195 221. S4.3.4-19. Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supra- ventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2016;133:e506 74. S4.3.4-20. Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease. Developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS) Heart Rhythm. 2014;11:e102 65. S4.3.4-21. Pediatric and Congenital Electrophysiology Society (PACES), Heart Rhythm Society (HRS), American College of Cardiology Foundation (ACCF), et al. PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff- Parkinson-White (WPW, ventricular preexcitation) electrocardio- graphic pattern. Developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS) Heart Rhythm. 2012;9:1006 24. 4.3.5. Tetralogy of Fallot S4.3.5-1. Knauth AL, Gauvreau K, Powell AJ, et al. Ventricular size and func- tion assessed by cardiac MRI predict major adverse clinical out- comes late after tetralogy of Fallot repair. Heart. 2008;94:211 6. S4.3.5-2. Morray BH, McElhinney DB, Cheatham JP, et al. Risk of coronary ar- tery compression among patients referred for transcatheter pulmo- nary valve implantation: a multicenter experience. Circ Cardiovasc Interv. 2013;6:535 42. S4.3.5-3. Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease. Developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS) Heart Rhythm. 2014;11:e102 65. S4.3.5-4. Dietl CA, Cazzaniga ME, Dubner SJ, et al. Life-threatening arrhyth- mias and RV dysfunction after surgical repair of tetralogy of Fallot. Comparison between transventricular and transatrial approaches. Circulation. 1994;90:II7 12. S4.3.5-5. Khairy P, Landzberg MJ, Gatzoulis MA, et al. Value of programmed ventricular stimulation after tetralogy of Fallot repair: a multicenter study. Circulation. 2004;109:1994 2000. S4.3.5-6. Tsai SF, Chan DP, Ro PS, et al. Rate of inducible ventricular ar- rhythmia in adults with congenital heart disease. Am J Cardiol. 2010;106:730 6. S4.3.5-7. Khairy P. Programmed ventricular stimulation for risk stratification in patients with tetralogy of Fallot: a Bayesian perspective. Nat Clin Pract Cardiovasc Med. 2007;4:292 3. CLINICAL STATEMENTS AND GUIDELINES S4.3.5-8. Lucron H, Mar on F, Bosser G, et al. Induction of sustained ven- tricular tachycardia after surgical repair of tetralogy of Fallot. Am J Cardiol. 1999;83:1369 73. S4.3.5-9. Ferraz Cavalcanti PE, S MPBO, Santos CA, et al. Pulmonary valve replacement after operative repair of tetralogy of Fallot: meta-anal- ysis and meta-regression of 3,118 patients from 48 studies. J Am Coll Cardiol. 2013;62:2227 43. S4.3.5-10. Gengsakul A, Harris L, Bradley TJ, et al. The impact of pulmonary valve replacement after tetralogy of Fallot repair: a matched com- parison. Eur J Cardiothorac Surg. 2007;32:462 8. S4.3.5-11. Discigil B, Dearani JA, Puga FJ, et al. Late pulmonary valve replace- ment after repair of tetralogy of Fallot. J Thorac Cardiovasc Surg. 2001;121:344 51. S4.3.5-12. Oosterhof T, van Straten A, Vliegen HW, et al. Preoperative thresh- olds for pulmonary valve replacement in patients with corrected tetralogy of Fallot using cardiovascular magnetic resonance. Circulation. 2007;116:545 51. S4.3.5-13. Lee C, Kim YM, Lee C-H, et al. Outcomes of pulmonary valve re- placement in 170 patients with chronic pulmonary regurgitation after relief of right ventricular outflow tract obstruction: implica- tions for optimal timing of pulmonary valve replacement. J Am Coll Cardiol. 2012;60:1005 14. S4.3.5-14. Geva T. Indications for pulmonary valve replacement in repaired tetralogy of Fallot: the quest continues. Circulation. 2013;128:1855 7. S4.3.5-15. Koyak Z, de Groot JR, Bouma BJ, et al. Symptomatic but not asymptomatic non-sustained ventricular tachycardia is associated with appropriate implantable cardioverter therapy in tetralogy of Fallot. Int J Cardiol. 2013;167:1532 5. S4.3.5-16. Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter- defibrillators in tetralogy of Fallot. Circulation. 2008;117:363 70. S4.3.5-17. Witte KK, Pepper CB, Cowan JC, et al. Implantable cardioverter- defibrillator therapy in adult patients with tetralogy of Fallot. Europace. 2008;10:926 30. S4.3.5-18. Nollert G, Fischlein T, Bouterwek S, et al. Long-term results of total repair of tetralogy of Fallot in adulthood: 35 years follow-up in 104 patients corrected at the age of 18 or older. Thorac Cardiovasc Surg. 1997;45:178 81. S4.3.5-19. Valente AM, Gauvreau K, Assenza GE, et al. Contemporary pre- dictors of death and sustained ventricular tachycardia in patients with repaired tetralogy of Fallot enrolled in the INDICATOR cohort. Heart. 2014;100:247 53. S4.3.5-20. Geva T, Sandweiss BM, Gauvreau K, et al. Factors associated with impaired clinical status in long-term survivors of tetralogy of Fallot repair evaluated by magnetic resonance imaging. J Am Coll Cardiol. 2004;43:1068 74. S4.3.5-21. Murphy JG, Gersh BJ, Mair DD, et al. Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. N Engl J Med. 1993;329:593 9. S4.3.5-22. Ghai A, Silversides C, Harris L, et al. Left ventricular dysfunction is a risk factor for sudden cardiac death in adults late after repair of tetralogy of Fallot. J Am Coll Cardiol. 2002;40:1675 80. S4.3.5-23. Geva T, Gauvreau K, Powell AJ, et al. Randomized trial of pulmo- nary valve replacement with and without right ventricular remodel- ing surgery. Circulation. 2010;122:S201 8. S4.3.5-24. Gatzoulis MA, Balaji S, Webber SA, et al. Risk factors for ar- rhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet. 2000;356:975 81. S4.3.5-25. Quail MA, Frigiola A, Giardini A, et al. Impact of pulmonary valve replacement in tetralogy of Fallot with pulmonary regurgitation: a comparison of intervention and nonintervention. Ann Thorac Surg. 2012;94:1619 26. S4.3.5-26. Wald RM, Lyseggen E, Oechslin EN, et al. Variability in surgical referral patterns for pulmonary valve replacement in adults with repaired tetralogy of Fallot. Congenit Heart Dis. 2009;4:231 8. S4.3.5-27. Therrien J, Provost Y, Merchant N, et al. Optimal timing for pulmo- nary valve replacement in adults after tetralogy of Fallot repair. Am J Cardiol. 2005;95:779 82. S4.3.5-28. Bonello B, Kempny A, Uebing A, et al. Right atrial area and right ventricular outflow tract akinetic length predict sustained tachyarrhythmia in repaired tetralogy of Fallot. Int J Cardiol. 2013;168:3280 6. S4.3.5-29. N rgaard MA, Lauridsen P, Helvind M, et al. Twenty-to-thirty- seven-year follow-up after repair for tetralogy of Fallot. Eur J Cardiothorac Surg. 1999;16:125 30. S4.3.5-30. Silka MJ, Hardy BG, Menashe VD, et al. A population-based prospec- tive evaluation of risk of sudden cardiac death after operation for com- mon congenital heart defects. J Am Coll Cardiol. 1998;32:245 51. S4.3.5-31. Norozi K, Bahlmann J, Raab B, et al. A prospective, randomized, double-blind, placebo controlled trial of beta-blockade in patients who have undergone surgical correction of tetralogy of Fallot. Cardiol Young. 2007;17:372 9. S4.3.5-32. Diller G-P, Kempny A, Liodakis E, et al. Left ventricular longitudinal function predicts life-threatening ventricular arrhythmia and death in adults with repaired tetralogy of Fallot. Circulation. 2012;125:2440 6. S4.3.5-33. Kella DK, Merchant FM, Veledar E, et al. Lesion-specific dif- ferences for implantable cardioverter defibrillator therapies in adults with congenital heart disease. Pacing Clin Electrophysiol. 2014;37:1492 8. S4.3.5-34. Kilner PJ, Geva T, Kaemmerer H, et al. Recommendations for car- diovascular magnetic resonance in adults with congenital heart di- sease from the respective working groups of the European Society of Cardiology. Eur Heart J. 2010;31:794 805. S4.3.5-35. Valente AM, Geva T. How to image repaired tetralogy of Fallot. Circ Cardiovasc Imaging. 2017;10. S4.3.5-36. Wald RM, Valente AM, Gauvreau K, et al. Cardiac magnetic res- onance markers of progressive RV dilation and dysfunction after tetralogy of Fallot repair. Heart. 2015;101:1724 30. S4.3.5-37. Bokma JP, Geva T, Sleeper LA, et al. A propensity score-adjusted analysis of clinical outcomes after pulmonary valve replacement in tetralogy of Fallot. Heart. 2017. S4.3.5-38. Khairy P, Fernandes SM, Mayer JE Jr, et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation. 2008;117:85 92. S4.3.5-39. Zubairi R, Malik S, Jaquiss RDB, et al. Risk factors for pros- thesis failure in pulmonary valve replacement. Ann Thorac Surg. 2011;91:561 5. S4.3.5-40. Cook SC, Valente AM, Maul TM, et al. Shock-related anxiety and sexual function in adults with congenital heart disease and implant- able cardioverter-defibrillators. Heart Rhythm. 2013;10:805 10. S4.3.5-41. Davlouros PA, Kilner PJ, Hornung TS, et al. Right ventricular func- tion in adults with repaired tetralogy of Fallot assessed with cardi- ovascular magnetic resonance imaging: detrimental role of right ventricular outflow aneurysms or akinesia and adverse right-to-left ventricular interaction. J Am Coll Cardiol. 2002;40:2044 52. S4.3.5-42. Harrild DM, Berul CI, Cecchin F, et al. Pulmonary valve replace- ment in tetralogy of Fallot: impact on survival and ventricular tach- ycardia. Circulation. 2009;119:445 51. S4.3.5-43. Downar E, Harris L, Kimber S, et al. Ventricular tachycardia after surgical repair of tetralogy of Fallot: results of intraoperative map- ping studies. J Am Coll Cardiol. 1992;20:648 55. 4.3.6. Right Ventricle to-Pulmonary Artery Conduit S4.3.6-1. Morray BH, McElhinney DB, Cheatham JP, et al. Risk of coronary ar- tery compression among patients referred for transcatheter pulmo- nary valve implantation: a multicenter experience. Circ Cardiovasc Interv. 2013;6:535 42. S4.3.6-2. Fraisse A, Assaidi A, Mauri L, et al. Coronary artery compression during intention to treat right ventricle outflow with percutaneous pulmonary valve implantation: incidence, diagnosis, and outcome. Catheter Cardiovasc Interv. 2014;83:E260 8. S4.3.6-3. McElhinney DB, Benson LN, Eicken A, et al. Infective endocarditis after transcatheter pulmonary valve replacement using the Melody valve: combined results of 3 prospective North American and European studies. Circ Cardiovasc Interv. 2013;6:292 300. S4.3.6-4. McElhinney DB, Cheatham JP, Jones TK, et al. Stent fracture, valve dysfunction, and right ventricular outflow tract reintervention after transcatheter pulmonary valve implantation: patient-related and procedural risk factors in the US Melody Valve Trial. Circ Cardiovasc Interv. 2011;4:602 14. S4.3.6-5. Mainwaring RD, Pirolli T, Punn R, et al. Late repair of the native pul- monary valve in patients with pulmonary insufficiency after surgery for tetralogy of Fallot. Ann Thorac Surg. 2012;93:677 9. S4.3.6-6. Bauer BS, Zachariah S, Levi D, et al. Evaluation of peak pressure gradients in patients after Melody valve implantation: a compar- ison of cardiac catheterization and doppler echocardiography. Echocardiography. 2015;32:1073 9. CLINICAL STATEMENTS AND GUIDELINES S4.3.6-7. McElhinney DB, Hellenbrand WE, Zahn EM, et al. Short- and medium-term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US Melody valve trial. Circulation. 2010;122:507 16. S4.3.6-8. Niemantsverdriet MBA, Ottenkamp J, Gauvreau K, et al. Determinants of right ventricular outflow tract conduit longevity: a multinational analysis. Congenit Heart Dis. 2008;3:176 84. S4.3.6-9. Batra AS, McElhinney DB, Wang W, et al. Cardiopulmonary exer- cise function among patients undergoing transcatheter pulmonary valve implantation in the US Melody valve investigational trial. Am Heart J. 2012;163:280 7. S4.3.6-10. Zahn EM, Hellenbrand WE, Lock JE, et al. Implantation of the Melody transcatheter pulmonary valve in patients with a dysfunc- tional right ventricular outflow tract conduit early results from the US clinical trial. J Am Coll Cardiol. 2009;54:1722 9. S4.3.6-11. Brown JW, Ruzmetov M, Rodefeld MD, et al. Right ventricular out- flow tract reconstruction in Ross patients: does the homograft fare better? Ann Thorac Surg. 2008;86:1607 12. S4.3.6-12. Frigiola A, Tsang V, Nordmeyer J, et al. Current approaches to pul- monary regurgitation. Eur J Cardiothorac Surg. 2008;34:576 80. S4.3.6-13. Lurz P, Nordmeyer J, Giardini A, et al. Early versus late functional outcome after successful percutaneous pulmonary valve implanta- tion: are the acute effects of altered right ventricular loading all we can expect? J Am Coll Cardiol. 2011;57:724 31. S4.3.6-14. Coats L, Khambadkone S, Derrick G, et al. Physiological and clin- ical consequences of relief of right ventricular outflow tract ob- struction late after repair of congenital heart defects. Circulation. 2006;113:2037 44. S4.3.6-15. Kloevekorn WP, Meisner H, Paek SU, et al. Long-term results after right ventricular outflow tract reconstruction with porcine biopros- thetic conduits. J Card Surg. 1991;6:624 6. S4.3.6-16. Champsaur G, Robin J, Curtil A, et al. Long-term clinical and he- modynamic evaluation of porcine valved conduits implanted from the right ventricle to the pulmonary artery. J Thorac Cardiovasc Surg. 1998;116:793 804. S4.3.6-17. Buber J, Bergersen L, Lock JE, et al. Bloodstream infections occurring in patients with percutaneously implanted bioprosthetic pulmonary valve: a single-center experience. Circ Cardiovasc Interv. 2013;6:301 10. S4.3.6-18. Van Dijck I, Budts W, Cools B, et al. Infective endocarditis of a trans- catheter pulmonary valve in comparison with surgical implants. Heart. 2015;101:788 93. S4.3.6-19. Malekzadeh-Milani S, Ladouceur M, Patel M, et al. Incidence and predictors of Melody valve endocarditis: a prospective study. Arch Cardiovasc Dis. 2015;108:97 106. S4.3.6-20. Amat-Santos IJ, Ribeiro HB, Urena M, et al. Prosthetic valve endo- carditis after transcatheter valve replacement: a systematic review. JACC Cardiovasc Interv. 2015;8:334 46. 4.4. Complex Lesions 4.4.1. Transposition of the Great Arteries 4.4.1.1. Transposition of the Great Arteries With Atrial Switch S4.4.1.1-1. Khairy P, Landzberg MJ, Gatzoulis MA, et al. Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts: a multicenter study. Circulation. 2006;113:2391 7. S4.4.1.1-2. Khairy P, Harris L, Landzberg MJ, et al. Sudden death and defibril- lators in transposition of the great arteries with intra-atrial baffles: a multicenter study. Circ Arrhythm Electrophysiol. 2008;1:250 7. S4.4.1.1-3. Zaragoza-Macias E, Zaidi A, Dendukuri N, et al. Medical therapy for systemic right ventricles: a systematic review (part 1) for the 2018 AHA/ACC guideline for the management of adults with congen- ital heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e000 000. S4.4.1.1-4. Bouallal R, Godart F, Francart C, et al. Interest of -blockers in patients with right ventricular systemic dysfunction. Cardiol Young. 2010;20:615 19. S4.4.1.1-5. Doughan ARK, McConnell ME, Book WM. Effect of beta block- ers (carvedilol or metoprolol XL) in patients with transposition of great arteries and dysfunction of the systemic right ventricle. Am J Cardiol. 2007;99:704 6. S4.4.1.1-6. Giardini A, Lovato L, Donti A, et al. A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tol- erance in patients with systemic right ventricle. Int J Cardiol. 2007;114:241 6. S4.4.1.1-7. Dos L, Pujadas S, Estruch M, et al. Eplerenone in systemic right ventricle: double blind randomized clinical trial. The EVEDES Study. Int J Cardiol. 2013;168:5167 73. S4.4.1.1-8. Tulevski II, Lee PL, Groenink M, et al. Dobutamine-induced in- crease of right ventricular contractility without increased stroke volume in adolescent patients with transposition of the great arteries: evaluation with magnetic resonance imaging. Int J Card Imaging. 2000;16:471 8. S4.4.1.1-9. Broberg CS. Cardiac magnetic imaging of the patient with an atrial switch palliation for transposition of the great arteries. Prog Pediatr Cardiol. 2014;38:49 55. S4.4.1.1-10. Babu-Narayan SV, Goktekin O, Moon JC, et al. Late gadolinium enhancement cardiovascular magnetic resonance of the sys- temic right ventricle in adults with previous atrial redirection surgery for transposition of the great arteries. Circulation. 2005;111:2091 8. S4.4.1.1-11. Kammeraad JAD, van Deurzen CHM, Sreeram N, et al. Predictors of sudden cardiac death after Mustard or Senning repair for transposition of the great arteries. J Am Coll Cardiol. 2004;44:1095 102. S4.4.1.1-12. Lubiszewska B, Gosiewska E, Hoffman P, et al. Myocardial perfu- sion and function of the systemic right ventricle in patients after atrial switch procedure for complete transposition: long-term fol- low-up. J Am Coll Cardiol. 2000;36:1365 70. 4.4.1.2. Transposition of the Great Arteries With Arterial Switch S4.4.1.2-1. Khairy P, Clair M, Fernandes SM, et al. Cardiovascular outcomes after the arterial switch operation for D-transposition of the great arteries. Circulation. 2013;127:331 9. S4.4.1.2-2. Kempny A, Wustmann K, Borgia F, et al. Outcome in adult patients after arterial switch operation for transposition of the great arteries. Int J Cardiol. 2013;167:2588 93. S4.4.1.2-3. Lim H-G, Kim W-H, Lee JR, et al. Long-term results of the ar- terial switch operation for ventriculo-arterial discordance. Eur J Cardiothorac Surg. 2013;43:325 34. S4.4.1.2-4. Ou P, Khraiche D, Celermajer DS, et al. Mechanisms of coronary complications after the arterial switch for transposition of the great arteries. J Thorac Cardiovasc Surg. 2013;145:1263 9. S4.4.1.2-5. Legendre A, Losay J, Touchot-Kon A, et al. Coronary events after arterial switch operation for transposition of the great arteries. Circulation. 2003;108 suppl 1:II186 90. S4.4.1.2-6. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart di- sease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:e521 643. S4.4.1.2-7. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/ AATS/PCNA/SCAI/STS guideline for the diagnosis and manage- ment of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354 471. S4.4.1.2-8. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/ AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130:1749 67. S4.4.1.2-9. Taylor AM, Dymarkowski S, Hamaekers P, et al. MR coronary an- giography and late-enhancement myocardial MR in children who underwent arterial switch surgery for transposition of great arter- ies. Radiology. 2005;234:542 7. CLINICAL STATEMENTS AND GUIDELINES S4.4.1.2-10. Losay J, Touchot A, Serraf A, et al. Late outcome after arte- rial switch operation for transposition of the great arteries. Circulation. 2001;104:I121 6. S4.4.1.2-11. Oda S, Nakano T, Sugiura J, et al. Twenty-eight years experi- ence of arterial switch operation for transposition of the great arteries in a single institution. Eur J Cardiothorac Surg. 2012;42: 674 9. 4.4.1.4. Congenitally Corrected Transposition of the Great Arteries S4.4.1.4-1. Lewis M, Ginns J, Rosenbaum M. Is systemic right ventricular function by cardiac MRI related to the degree of tricuspid regur- gitation in congenitally corrected transposition of the great arter- ies? Int J Cardiol. 2014;174:586 9. S4.4.1.4-2. Grewal J, Crean A, Garceau P, et al. Subaortic right ventricular characteristics and relationship to exercise capacity in congeni- tally corrected transposition of the great arteries. J Am Soc Echocardiogr. 2012;25:1215 21. S4.4.1.4-3. Mongeon F-P, Connolly HM, Dearani JA, et al. Congenitally cor- rected transposition of the great arteries ventricular function at the time of systemic atrioventricular valve replacement predicts long-term ventricular function. J Am Coll Cardiol. 2011;57: 2008 17. S4.4.1.4-4. Prieto LR, Hordof AJ, Secic M, et al. Progressive tricuspid valve di- sease in patients with congenitally corrected transposition of the great arteries. Circulation. 1998;98:997 1005. S4.4.1.4-5. Buber J, McElhinney DB, Valente AM, et al. Tricuspid valve regur- gitation in congenitally corrected transposition of the great arter- ies and a left ventricle to pulmonary artery conduit. Ann Thorac Surg. 2015;99:1348 56. S4.4.1.4-6. Graham TP Jr, Bernard YD, Mellen BG, et al. Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional study. J Am Coll Cardiol. 2000;36:255 61. S4.4.1.4-7. Huhta JC, Maloney JD, Ritter DG, et al. Complete atrioventricular block in patients with atrioventricular discordance. Circulation. 1983;67:1374 7. S4.4.1.4-8. Anderson RH, Becker AE, Arnold R, et al. The conducting tis- sues in congenitally corrected transposition. Circulation. 1974;50:911 23. S4.4.1.4-9. van Son JA, Danielson GK, Huhta JC, et al. Late results of systemic atrioventricular valve replacement in corrected transposition. J Thorac Cardiovasc Surg. 1995;109:642 52. S4.4.1.4-10. Zaragoza-Macias E, Zaidi A, Dendukuri N, et al. Medical therapy for systemic right ventricles: a systematic review (part 1) for the 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e000 000. S4.4.1.4-11. Dore A, Houde C, Chan K-L, et al. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation. 2005;112:2411 6. S4.4.1.4-12. Therrien J, Provost Y, Harrison J, et al. Effect of angiotensin re- ceptor blockade on systemic right ventricular function and size: a small, randomized, placebo-controlled study. Int J Cardiol. 2008;129:187 92. S4.4.1.4-13. van der Bom T, Winter MM, Bouma BJ, et al. Effect of valsar- tan on systemic right ventricular function: a double-blind, ran- domized, placebo-controlled pilot trial. Circulation. 2013;127: 322 30. S4.4.1.4-14. Giardini A, Lovato L, Donti A, et al. Relation between right ven- tricular structural alterations and markers of adverse clinical outcome in adults with systemic right ventricle and either con- genital complete (after Senning operation) or congenitally cor- rected transposition of the great arteries. Am J Cardiol. 2006;98: 1277 82. S4.4.1.4-15. Scherptong RWC, Vliegen HW, Winter MM, et al. Tricuspid valve surgery in adults with a dysfunctional systemic right ventricle: re- pair or replace? Circulation. 2009;119:1467 72. S4.4.1.4-16. Beauchesne LM, Warnes CA, Connolly HM, et al. Outcome of the unoperated adult who presents with congenitally corrected transposition of the great arteries. J Am Coll Cardiol. 2002;40: 285 90. 4.4.2. Fontan Palliation of Single Ventricle Physiology (Including Tricuspid Atresia and Double Inlet Left Ventricle) S4.4.2-1. Khairy P, Fernandes SM, Mayer JE Jr, et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation. 2008;117:85 92. S4.4.2-2. Gatzoulis MA, Munk MD, Williams WG, et al. Definitive palliation with cavopulmonary or aortopulmonary shunts for adults with single ventricle physiology. Heart. 2000;83:51 7. S4.4.2-3. Cordina R, O Meagher S, Gould H, et al. Skeletal muscle abnor- malities and exercise capacity in adults with a Fontan circulation. Heart. 2013;99:1530 4. S4.4.2-4. Dulfer K, Duppen N, Blom NA, et al. Effects of exercise training on behavioral and emotional problems in adolescents with tetralogy of Fallot or a Fontan circulation: a randomized controlled trial. Int J Cardiol. 2014;172:e425 7. S4.4.2-5. Inai K, Saita Y, Takeda S, et al. Skeletal muscle hemodynamics and endothelial function in patients after Fontan operation. Am J Cardiol. 2004;93:792 7. S4.4.2-6. Kiesewetter CH, Sheron N, Vettukattill JJ, et al. Hepatic changes in the failing Fontan circulation. Heart. 2007;93:579 84. S4.4.2-7. Seddio F, Gorislavets N, Iacovoni A, et al. Is heart transplantation for complex congenital heart disease a good option? A 25-year single centre experience. Eur J Cardiothorac Surg. 2013;43: 605 11. S4.4.2-8. Hebson CL, McCabe NM, Elder RW, et al. Hemodynamic pheno- type of the failing Fontan in an adult population. Am J Cardiol. 2013;112:1943 7. S4.4.2-9. Davies RR, Sorabella RA, Yang J, et al. Outcomes after transplan- tation for failed Fontan: a single-institution experience. J Thorac Cardiovasc Surg. 2012;143:1183 92, e4. S4.4.2-10. Gamba A, Merlo M, Fiocchi R, et al. Heart transplantation in patients with previous Fontan operations. J Thorac Cardiovasc Surg. 2004;127:555 62. S4.4.2-11. Jayakumar KA, Addonizio LJ, Kichuk-Chrisant MR, et al. Cardiac transplantation after the Fontan or Glenn procedure. J Am Coll Cardiol. 2004;44:2065 72. S4.4.2-12. Backer CL, Russell HM, Pahl E, et al. Heart transplantation for the failing Fontan. Ann Thorac Surg. 2013;96:1413 9. S4.4.2-13. Triedman JK. Arrhythmias in adults with congenital heart disease. Heart. 2002;87:383 9. S4.4.2-14. Yap S-C, Harris L, Silversides CK, et al. Outcome of intra-atrial re-entrant tachycardia catheter ablation in adults with congenital heart disease: negative impact of age and complex atrial surgery. J Am Coll Cardiol. 2010;56:1589 96. S4.4.2-15. de Groot NMS, Atary JZ, Blom NA, et al. Long-term outcome after ablative therapy of postoperative atrial tachyarrhythmia in patients with congenital heart disease and characteristics of atrial tachyarrhythmia recurrences. Circ Arrhythm Electrophysiol. 2010;3:148 54. S4.4.2-16. Aboulhosn J, Williams R, Shivkumar K, et al. Arrhythmia recurrence in adult patients with single ventricle physiology following surgical Fontan conversion. Congenit Heart Dis. 2010;5:430 4. S4.4.2-17. Mavroudis C, Deal BJ, Backer CL, et al. J. Maxwell Chamberlain Memorial Paper for congenital heart surgery. 111 Fontan conver- sions with arrhythmia surgery: surgical lessons and outcomes. Ann Thorac Surg. 2007;84:1457 65. S4.4.2-18. Takahashi K, Fynn-Thompson F, Cecchin F, et al. Clinical outcomes of Fontan conversion surgery with and without associated ar- rhythmia intervention. Int J Cardiol. 2009;137:260 6. S4.4.2-19. Hebert A, Mikkelsen UR, Thilen U, et al. Bosentan improves ex- ercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study. Circulation. 2014;130:2021 30. S4.4.2-20. Giardini A, Balducci A, Specchia S, et al. Effect of sildenafil on hae- modynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J. 2008;29:1681 7. S4.4.2-21. Goldberg DJ, French B, McBride MG, et al. Impact of oral silden- afil on exercise performance in children and young adults after the Fontan operation: a randomized, double-blind, placebo-con- trolled, crossover trial. Circulation. 2011;123:1185 93. CLINICAL STATEMENTS AND GUIDELINES S4.4.2-22. Ovaert C, Thijs D, Dewolf D, et al. The effect of bosentan in patients with a failing Fontan circulation. Cardiol Young. 2009;19: 331 9. S4.4.2-23. Bowater SE, Weaver RA, Thorne SA, et al. The safety and effects of bosentan in patients with a Fontan circulation. Congenit Heart Dis. 2012;7:243 9. S4.4.2-24. Derk G, Houser L, Miner P, et al. Efficacy of endothelin blockade in adults with Fontan physiology. Congenit Heart Dis. 2015;10:E11 6. S4.4.2-25. Schuuring MJ, Vis JC, van Dijk APJ, et al. Impact of bosentan on ex- ercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail. 2013;15:690 8. S4.4.2-26. Potter BJ, Leong-Sit P, Fernandes SM, et al. Effect of aspirin and warfarin therapy on thromboembolic events in patients with univentricular hearts and Fontan palliation. Int J Cardiol. 2013;168:3940 3. S4.4.2-27. Harper AR, Crossland DS, Perri G, et al. Is alternative cardiac sur- gery an option in adults with congenital heart disease referred for thoracic organ transplantation? Eur J Cardiothorac Surg. 2013;43:344 51. S4.4.2-28. John AS, Driscoll DJ, Warnes CA, et al. The use of oral budesonide in adolescents and adults with protein-losing enteropathy after the Fontan operation. Ann Thorac Surg. 2011;92:1451 6. S4.4.2-29. Schumacher KR, Cools M, Goldstein BH, et al. Oral budesonide treatment for protein-losing enteropathy in Fontan-palliated patients. Pediatr Cardiol. 2011;32:966 71. S4.4.2-30. John AS, Phillips SD, Driscoll DJ, et al. The use of octreotide to successfully treat protein-losing enteropathy following the Fontan operation. Congenit Heart Dis. 2011;6:653 6. S4.4.2-31. John AS, Johnson JA, Khan M, et al. Clinical outcomes and improved survival in patients with protein-losing enteropathy after the Fontan operation. J Am Coll Cardiol. 2014;64:54 62. S4.4.2-32. Nakagawa H, Shah N, Matsudaira K, et al. Characterization of reentrant circuit in macroreentrant right atrial tachycardia after sur- gical repair of congenital heart disease: isolated channels between scars allow focal ablation. Circulation. 2001;103:699 709. S4.4.2-33. K rer CC, Tanner CS, Vetter VL. Electrophysiologic findings after Fontan repair of functional single ventricle. J Am Coll Cardiol. 1991;17:174 81. S4.4.2-34. Gelatt M, Hamilton RM, McCrindle BW, et al. Risk factors for atrial tachyarrhythmias after the Fontan operation. J Am Coll Cardiol. 1994;24:1735 41. S4.4.2-35. De Groot NM, Kuijper AF, Blom NA, et al. Three-dimensional distri- bution of bipolar atrial electrogram voltages in patients with con- genital heart disease. Pacing Clin Electrophysiol. 2001;24:1334 42. S4.4.2-36. Cohen MI, Bridges ND, Gaynor JW, et al. Modifications to the cavopulmonary anastomosis do not eliminate early sinus node dys- function. J Thorac Cardiovasc Surg. 2000;120:891 900. S4.4.2-37. Balaji S, Daga A, Bradley DJ, et al. An international multicenter study comparing arrhythmia prevalence between the intracardiac lateral tunnel and the extracardiac conduit type of Fontan opera- tions. J Thorac Cardiovasc Surg. 2014;148:576 81. S4.4.2-38. de Groot NMS, Schalij MJ, Zeppenfeld K, et al. Voltage and activa- tion mapping: how the recording technique affects the outcome of catheter ablation procedures in patients with congenital heart disease. Circulation. 2003;108:2099 106. S4.4.2-39. Cohen MI, Vetter VL, Wernovsky G, et al. Epicardial pacemaker im- plantation and follow-up in patients with a single ventricle after the Fontan operation. J Thorac Cardiovasc Surg. 2001;121:804 11. S4.4.2-40. Gentles TL, Gauvreau K, Mayer JE Jr, et al. Functional outcome after the Fontan operation: factors influencing late morbidity. J Thorac Cardiovasc Surg. 1997;114:392 403. S4.4.2-41. Cohen MI, Wernovsky G, Vetter VL, et al. Sinus node func- tion after a systematically staged Fontan procedure. Circulation. 1998;98:II352 8. S4.4.2-42. Barber BJ, Burch GH, Tripple D, et al. Resolution of plastic bron- chitis with atrial pacing in a patient with Fontan physiology. Pediatr Cardiol. 2004;25:73 6. S4.4.2-43. Nielsen JC, Pedersen AK, Mortensen PT, et al. Programming a fixed long atrioventricular delay is not effective in preventing ven- tricular pacing in patients with sick sinus syndrome. Europace. 1999;1:113 20. S4.4.2-44. Abrams DJ, Earley MJ, Sporton SC, et al. Comparison of noncon- tact and electroanatomic mapping to identify scar and arrhythmia late after the Fontan procedure. Circulation. 2007;115:1738 46. S4.4.2-45. Rosenthal E, Qureshi SA, Crick JC. Successful long-term ventricular pacing via the coronary sinus after the Fontan operation. Pacing Clin Electrophysiol. 1995;18:2103 5. S4.4.2-46. Blackburn ME, Gibbs JL. Ventricular pacing from the coronary sinus of a patient with a Fontan circulation. Br Heart J. 1993;70:578 9. S4.4.2-47. Walsh EP, Cecchin F. Arrhythmias in adult patients with congenital heart disease. Circulation. 2007;115:534 5. S4.4.2-48. Piran S, Veldtman G, Siu S, et al. Heart failure and ventricular dysfunction in patients with single or systemic right ventricles. Circulation. 2002;105:1189 94. S4.4.2-49. Wells R, Khairy P, Harris L, et al. Dofetilide for atrial arrhythmias in congenital heart disease: a multicenter study. Pacing Clin Electrophysiol. 2009;32:1313 8. S4.4.2-50. Thorne SA, Barnes I, Cullinan P, et al. Amiodarone-associated thy- roid dysfunction: risk factors in adults with congenital heart di- sease. Circulation. 1999;100:149 54. S4.4.2-51. Garg R, Powell AJ, Sena L, et al. Effects of metallic implants on magnetic resonance imaging evaluation of Fontan palliation. Am J Cardiol. 2005;95:688 91. S4.4.2-52. Prabhu SP, Mahmood S, Sena L, et al. MDCT evaluation of pul- monary embolism in children and young adults following a lateral tunnel Fontan procedure: optimizing contrast-enhancement tech- niques. Pediatr Radiol. 2009;39:938 44. S4.4.2-53. Asrani SK, Warnes CA, Kamath PS. Hepatocellular carcinoma after the Fontan procedure. N Engl J Med. 2013;368:1756 7. S4.4.2-54. Ono M, Boethig D, Goerler H, et al. Clinical outcome of patients 20 years after Fontan operation effect of fenestration on late mor- bidity. Eur J Cardiothorac Surg. 2006;30:923 9. S4.4.2-55. Atz AM, Travison TG, McCrindle BW, et al. Late status of Fontan patients with persistent surgical fenestration. J Am Coll Cardiol. 2011;57:2437 43. S4.4.2-56. Poterucha JT, Johnson JN, Taggart NW, et al. Embolization of veno- venous collaterals after the Fontan operation is associated with decreased survival. Congenit Heart Dis. 2015;10:E230 6. S4.4.2-57. Mets JM, Bergersen L, Mayer JE Jr, et al. Outcomes of stent implan- tation for obstruction of intracardiac lateral tunnel Fontan path- ways. Circ Cardiovasc Interv. 2013;6:92 100. S4.4.2-58. Ohuchi H, Yasuda K, Miyazaki A, et al. Haemodynamic charac- teristics before and after the onset of protein losing enteropathy in patients after the Fontan operation. Eur J Cardiothorac Surg. 2013;43:e49 57. S4.4.2-59. Downing TE, McDonnell A, Zhu X, et al. Cumulative medical ra- diation exposure throughout staged palliation of single ventricle congenital heart disease. Pediatr Cardiol. 2015;36:190 5. S4.4.2-60. Mahnke CB, Boyle GJ, Janosky JE, et al. Anticoagulation and inci- dence of late cerebrovascular accidents following the Fontan pro- cedure. Pediatr Cardiol. 2005;26:56 61. S4.4.2-61. Triedman JK, Alexander ME, Love BA, et al. Influence of patient factors and ablative technologies on outcomes of radiofrequency ablation of intra-atrial re-entrant tachycardia in patients with con- genital heart disease. J Am Coll Cardiol. 2002;39:1827 35. S4.4.2-62. Deal BJ, Mavroudis C, Backer CL, et al. Comparison of ana- tomic isthmus block with the modified right atrial maze proce- dure for late atrial tachycardia in Fontan patients. Circulation. 2002;106:575 9. S4.4.2-63. Rychik J, Veldtman G, Rand E, et al. The precarious state of the liver after a Fontan operation: summary of a multidisciplinary sympo- sium. Pediatr Cardiol. 2012;33:1001 12. S4.4.2-64. Monagle P, Cochrane A, Roberts R, et al. A multicenter, random- ized trial comparing heparin/warfarin and acetylsalicylic acid as pri- mary thromboprophylaxis for 2 years after the Fontan procedure in children. J Am Coll Cardiol. 2011;58:645 51. S4.4.2-65. McCrindle BW, Manlhiot C, Cochrane A, et al. Factors associ- ated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure. J Am Coll Cardiol. 2013;61:346 53. 4.4.6. Severe PAH and Eisenmenger Syndrome 4.4.6.1. Severe PAH S4.4.6.1-1. D Alto M, Romeo E, Argiento P, et al. Hemodynamics of patients developing pulmonary arterial hypertension after shunt closure. Int J Cardiol. 2013;168:3797 801. CLINICAL STATEMENTS AND GUIDELINES S4.4.6.1-2. Barst RJ, Ivy DD, Foreman AJ, et al. Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry). Am J Cardiol. 2014;113:147 55. S4.4.6.1-3. Duffels MGJ, Engelfriet PM, Berger RMF, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic per- spective from a Dutch registry. Int J Cardiol. 2007;120:198 204. S4.4.6.1-4. Engelfriet PM, Duffels MGJ, M ller T, et al. Pulmonary arte- rial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart. 2007;93:682 7. S4.4.6.1-5. Lowe BS, Therrien J, Ionescu-Ittu R, et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population im- pact on outcomes. J Am Coll Cardiol. 2011;58:538 46. S4.4.6.1-6. Manes A, Palazzini M, Leci E, et al. Current era survival of patients with pulmonary arterial hypertension associated with congen- ital heart disease: a comparison between clinical subgroups. Eur Heart J. 2014;35:716 24. S4.4.6.1-7. Gabriels C, De Meester P, Pasquet A, et al. A different view on predictors of pulmonary hypertension in secundum atrial septal defect. Int J Cardiol. 2014;176:833 40. S4.4.6.1-8. O Donnell C, Ruygrok PN, Whyte K, et al. Progressive pulmonary hypertension post atrial septal defect device closure-early symp- tomatic improvement may not predict outcome. Heart Lung Circ. 2010;19:713 6. S4.4.6.1-9. Van De Bruaene A, Delcroix M, Pasquet A, et al. The importance of pulmonary artery pressures on late atrial arrhythmia in trans- catheter and surgically closed ASD type secundum. Int J Cardiol. 2011;152:192 5. S4.4.6.1-10. Van De Bruaene A, Moons P, Belmans A, et al. Predictive model for late atrial arrhythmia after closure of an atrial septal defect. Int J Cardiol. 2013;164:318 22. S4.4.6.1-11. Berner M, Beghetti M, Spahr-Schopfer I, et al. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congen- ital heart disease. Am J Cardiol. 1996;77:532 5. S4.4.6.1-12. Balint OH, Samman A, Haberer K, et al. Outcomes in patients with pulmonary hypertension undergoing percutaneous atrial septal defect closure. Heart. 2008;94:1189 93. S4.4.6.1-13. Gorenflo M, Gu H, Xu Z. Peri-operative pulmonary hypertension in paediatric patients: current strategies in children with congen- ital heart disease. Cardiology. 2010;116:10 7. S4.4.6.1-14. Huang J-B, Liu Y-L, Yu C-T, et al. Lung biopsy findings in previously inoperable patients with severe pulmonary hypertension associ- ated with congenital heart disease. Int J Cardiol. 2011;151:76 83. S4.4.6.1-15. Neutze JM, Ishikawa T, Clarkson PM, et al. Assessment and fol- low-up of patients with ventricular septal defect and elevated pul- monary vascular resistance. Am J Cardiol. 1989;63:327 31. S4.4.6.1-16. Steele PM, Fuster V, Cohen M, et al. Isolated atrial septal defect with pulmonary vascular obstructive disease long-term follow-up and prediction of outcome after surgical correction. Circulation. 1987;76:1037 42. S4.4.6.1-17. Yong G, Khairy P, De Guise P, et al. Pulmonary arterial hyper- tension in patients with transcatheter closure of secundum atrial septal defects: a longitudinal study. Circ Cardiovasc Interv. 2009;2:455 62. S4.4.6.1-18. Balzer DT, Kort HW, Day RW, et al. Inhaled nitric oxide as a preop- erative test (INOP Test I): the INOP Test Study Group. Circulation. 2002;106:I76 81. S4.4.6.1-19. Opotowsky AR, Ojeda J, Rogers F, et al. A simple echocardio- graphic prediction rule for hemodynamics in pulmonary hyper- tension. Circ Cardiovasc Imaging. 2012;5:765 75. S4.4.6.1-20. Opotowsky AR, Clair M, Afilalo J, et al. A simple echocardio- graphic method to estimate pulmonary vascular resistance. Am J Cardiol. 2013;112:873 82. S4.4.6.1-21. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D34 41. 4.4.6.2. Eisenmenger Syndrome S4.4.6.2-1. Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving ad- vanced therapy for pulmonary arterial hypertension. Circulation. 2010;121:20 5. S4.4.6.2-2. Gatzoulis MA, Beghetti M, Gali N, et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008;127:27 32. S4.4.6.2-3. Gali N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, dou- ble-blind, randomized, placebo-controlled study. Circulation. 2006;114:48 54. S4.4.6.2-4. Diller G-P, Alonso-Gonzalez R, Dimopoulos K, et al. Disease targeting therapies in patients with Eisenmenger syndrome: re- sponse to treatment and long-term efficiency. Int J Cardiol. 2013;167:840 7. S4.4.6.2-5. D Alto M, Romeo E, Argiento P, et al. Therapy for pulmonary ar- terial hypertension due to congenital heart disease and Down s syndrome. Int J Cardiol. 2013;164:323 6. S4.4.6.2-6. Iversen K, Jensen AS, Jensen TV, et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a ran- domized, placebo-controlled, double-blinded trial. Eur Heart J. 2010;31:1124 31. S4.4.6.2-7. Baptista R, Castro G, da Silva AM, et al. Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease. Rev Port Cardiol. 2013;32:123 9. S4.4.6.2-8. Crepaz R, Romeo C, Montanaro D, et al. Long-term results of treatment with bosentan in adult Eisenmenger s syndrome patients with Down s syndrome related to congenital heart di- sease. BMC Cardiovasc Disord. 2013;13:74. S4.4.6.2-9. Duffels MGJ, Vis JC, van Loon RLE, et al. Down patients with Eisenmenger syndrome: is bosentan treatment an option? Int J Cardiol. 2009;134:378 83. S4.4.6.2-10. Serino G, Guazzi M, Micheletti A, et al. Effect of bosentan on exercise capacity and clinical worsening in patients with dual Down and Eisenmenger syndrome. Clin Med Insights Cardiol. 2013;7:29 34. S4.4.6.2-11. Zhang Z-N, Jiang X, Zhang R, et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart. 2011;97:1876 81. S4.4.6.2-12. Garg N, Tripathy N, Sinha N. Comparative efficacy of sildenafil in Eisenmenger s syndrome secondary to atrial septal defect versus ventricular septal defect: a cardiac catheterisation follow-up study. Cardiol Young. 2011;21:631 8. S4.4.6.2-13. Tay ELW, Papaphylactou M, Diller G-P, et al. Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy. Int J Cardiol. 2011;149:372 6. S4.4.6.2-14. Bharani A, Patel A, Saraf J, et al. Efficacy and safety of PDE-5 in- hibitor tadalafil in pulmonary arterial hypertension. Indian Heart J. 2007;59:323 8. S4.4.6.2-15. Mukhopadhyay S, Sharma M, Ramakrishnan S, et al. Phosphodiesterase-5 inhibitor in Eisenmenger syndrome: a pre- liminary observational study. Circulation. 2006;114:1807 10. S4.4.6.2-16. Singh TP, Rohit M, Grover A, et al. A randomized, placebo-con- trolled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151:851.e1 851.e5. S4.4.6.2-17. Gali N, Hoeper MM, Humbert M, et al. Guidelines for the diag- nosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2009;30:2493 537. S4.4.6.2-18. D Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil associa- tion in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. 2012;155:378 82. 4.4.7. Coronary Anomalies S4.4.7-1. Eckart RE, Shry EA, Burke AP, et al. Sudden death in young adults: an autopsy-based series of a population undergoing active sur- veillance. J Am Coll Cardiol. 2011;58:1254 61. S4.4.7-2. Krasuski RA, Magyar D, Hart S, et al. 